Skip to main content

Allogene Therapeutics, Inc.

corporate_fare Company Profile

Allogene Therapeutics, Inc.

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Exchange: NASDAQSector: Life Sciences

show_chartPrice Chart

Loading chart...

feed ALLO - Latest Insights

ALLO
Apr 21, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
ALLO
Apr 20, 2026, 5:21 PM EDT
Filing Type: PRE 14A
Importance Score:
8
ALLO
Apr 16, 2026, 4:45 PM EDT
Source: Reuters
Importance Score:
8
ALLO
Apr 15, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
ALLO
Apr 15, 2026, 4:33 PM EDT
Filing Type: 424B5
Importance Score:
8
ALLO
Apr 13, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
ALLO
Apr 13, 2026, 4:01 PM EDT
Source: GlobeNewswire
Importance Score:
8
ALLO
Apr 13, 2026, 7:45 AM EDT
Filing Type: 8-K
Importance Score:
9
ALLO
Apr 13, 2026, 7:30 AM EDT
Source: GlobeNewswire
Importance Score:
9
ALLO
Mar 12, 2026, 4:15 PM EDT
Source: Wiseek News
Importance Score:
9
ALLO
Mar 12, 2026, 4:11 PM EDT
Filing Type: 10-K
Importance Score:
8
ALLO
Mar 12, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
8